Clinical trials
catalyst calendar across sponsors →Studies where LXEO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 3 observational
Held by 8 tracked-famous managers (CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Balyasny Asset Management L.P., Qube Research & Technologies Ltd, Squarepoint Ops LLC, +3 more) · FINRA short interest 16.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of LX2006 Gene Therapy in Friedreich Ataxia CardiomyopathyNCT07721025Percent change from baseline in left ventricular mass index by cardiac MRIRandomized · Single-masked · Treatment | Phase 2 | Recruiting | Genetic: LX2006 · Other: Usual Care | Friedreich Ataxia, Cardiomyopathy, Secondary | 26 | Jun 2032 | ≤ 2,142 d | 2026-07-22 |
| Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic VariantNCT07050160observationalPercentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE). | — | Enrolling by invitation | — | Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC | 10 | Aug 2030 | ≤ 1,473 d | 2025-11-12 |
| Gene Therapy for Cardiomyopathy Associated With Friedreich's AtaxiaNCT05445323Treatment-emergent adverse events (TEAEs) and Treatment-emergent serious events (TESAEs)Open-label · Treatment | Phase 1/2 | Active, not recruiting | Genetic: Low dose LX2006, Mid Dose LX2006, High Dose LX2006 | Friedreich Ataxia, Cardiomyopathy, Secondary | 8 | Sep 2029 | ≤ 1,138 d | 2025-12-23 |
| Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's DiseaseNCT05400330Incidence of treatment emergent adverse eventsOpen-label · Treatment | Phase 1 | Active, not recruiting | Biological: LX1001 | Alzheimer Disease | 10 | Nov 2028 | ≤ 834 d | 2025-07-01 |
| Clinical Course Of Disease In Participants With FA-CMNCT06865482observationalCharacterize cardiac disease presentation and progression among participants | — | Recruiting | — | Friedreich Ataxia, Cardiomyopathy | 65 | Sep 2027 | ≤ 407 d | 2026-06-08 |
| A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACMNCT06976606observationalPremature ventricular contractions (PVC) | — | Recruiting | — | Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC | 40 | Jul 2027 | ≤ 346 d | 2025-05-16 |
| Gene Therapy for ACM Due to a PKP2 Pathogenic VariantNCT06109181Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).Open-label · Treatment | Phase 1/2 | Active, not recruiting | Genetic: LX2020 | Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC | 10 | Dec 2026 | ≤ 134 d | 2025-11-12 |
| Gene Therapy for APOE4 Homozygote of Alzheimer's DiseaseNCT03634007Proportion of participants with treatment-emergent adverse events and serious adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: LX1001 | Alzheimer Disease, Early Onset Alzheimer Disease | 15 | 2024-11-07actual | — | 2025-10-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19